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TDR, the Special Programme for
Research and Training in Tropical Dis-
eases, was launched in 1978, more or less
the same year I began my career in science
as a Yale undergraduate working on the
then nascent molecular biology of anti-
genic variation in African trypanosomes.
Over the next two decades as a MD PhD
student working on hookworms at Rock-
efeller University, and then back at Yale as
a postdoctoral fellow and a member of the
junior faculty there, I was told on multiple
occasions that the likelihood of my making
a career in scientific research on neglected
tropical diseases was not very promising.
After all, neglected diseases were neglected
for a reason, including the fact that the
most promising options for my obtaining
long-term support at that time were (by
today’s standards) relatively modest funds
from the Rockefeller Foundation, the John
D. and Catherine T. MacArthur Founda-
tion, the Burroughs Wellcome Fund
(BWF), and the US National Institutes of
Health (NIH) tropical medicine and par-
asitology study section. However, it turned
out that through the establishment of some
innovative networks, the stewards of those
funding organizations were remarkably
adept at leveraging those modest dollars
into keeping alive a sustained effort for
neglected tropical disease research. This
carried the US neglected disease research
community all the way until 1999, when
funding scaled up dramatically with the
entry of the Bill & Melinda Gates
Foundation. Today, the support of the
Gates Foundation is now being used to
successfully leverage much of that earlier
Rockefeller, BWF, MacArthur, Wellcome
Trust, and NIH driven fundamental
research into the development of new
products and clinical testing for the major
neglected tropical diseases.
Internationally, over the last 30 years
the world has looked to TDR as a
dependable supporter and innovator for
research in tropical diseases. Through this
period, the successes of almost all of my
major overseas scientific collaborators
depended heavily on TDR support, and
TDR made it possible for literally hun-
dreds of middle- and low-income country
investigators to maintain meaningful sci-
entific careers without leaving laboratories
located in their native countries. TDR-
funded research also provided a significant
base for establishing our current genera-
tion of tropical disease products. Because
of TDR and its joint activities with
Rockefeller, Wellcome, and NIH, we
now have in place an impressive overseas
network of tropical disease research labo-
ratories in Africa, Asia, and the Americas.
The 250 peer-reviewed scientific papers
published annually by TDR-supported
scientists and laboratories (many of which
appear regularly in PLoS Neglected Tropical
Diseases) are a testament to good decision-
making by the TDR and the productivity
of its grantees. Today, these same TDR-
supported laboratories are now playing a
critical role in the product development
and clinical testing activities supported by
the Gates Foundation and other organi-
zations. For example, our Human Hook-
worm Vaccine Initiative was able to hit the
ground running upon receiving Gates
Foundation funds in part because of strong
overseas infrastructures established with
the help of TDR support at the Rene
Rachou Research Centre of the Oswaldo
Cruz Foundation (FIOCRUZ) in Belo
Horizonte, Brazil, and the Institute of
Parasitic Diseases in Shanghai, China.
When it was launched 30 years ago,
TDR had to be by necessity ‘‘everything to
everybody,’’ meaning that they were one
of the only games in town and laboratories
everywhere depended on their support for
basic science, translational research, prod-
uct development, and clinical testing.
However, as global health research sup-
port has increased and the 10/90 gap is
slowly being bridged, this soup to nuts
approach to tropical diseases is no longer
necessary. This month in PLoS Neglected
Tropical Diseases, we examine the shifting
priorities of TDR and its future through
four articles, including a summary of its
Fourth External Review completed in
2006 by Professor Abdallah Daar and his
colleagues [1], a viewpoint from the TDR
leadership [2], including its director, Dr.
Robert Ridley, and two commentaries
written by Dr. Anthony Mbewu of South
Africa’s Medical Research Council and
Drs. Daniel Carucci and Michael Gottlieb
of the Foundation for the NIH, respec-
tively [3,4]. In an upcoming issue, we are
publishing a Viewpoint from scientists in
Kenya [5] (which complements an earlier
August 2008 Viewpoint article by Drs.
Garcia and Curioso from Peru [6]) on the
challenges of retaining high quality scien-
tists and maintaining scientific infrastruc-
ture in developing countries.
From these articles I can see some clear
trends emerging. No organization, even
well-resourced ones like the Gates Foun-
dation, can any longer afford the luxury of
being everything to everybody. The new
global health initiatives and their mandate
to fulfill Millennium Development Goal 6,
‘‘to combat HIV/AIDS, malaria and
other diseases,’’ have simply become too
big and too complex for any single
organization to take on this entire task.
In the interval year period between the
Third and Fourth External Reviews, it
could be argued that there was an
unprecedented revolution in global health
support and advocacy, one that brought in
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nations, massive private donor support,
and a new generation of eager global
health celebrities. It stands to reason,
therefore, that the two reviews conducted
in 1998 and 2006, respectively, might
express opposite views. The first few years
of the 21st century were a time of great
transition in our field, and as the head of a
product development partnership, I can
certainly empathize with any leader who
ran a global health organization during
that time. It must be a particular challenge
for the head of a United Nations organi-
zation like TDR, which by their compli-
cated charter must appeal to a wide
diversity of constituents.
In the article written by the TDR
leadership, Ridley et al. express the view
that because their organization works
through partners in ways that promote
their achievement, the achievements of
TDR may sometimes be undervalued [2].
Those of us who have worked in the field
of tropical medicine these last three
decades deeply value the accomplishments
of TDR. I also agree with their statement
that TDR should be seen as a highly
significant and successful entity, particu-
larly ‘‘when judged against its budget.’’ At
PLoS Neglected Tropical Diseases, we look
forward to the coming years in order to see
how the TDR responds to new challenges
and mandates and retains their essential
role in what has become a far more
complicated and involved, albeit more
interesting, space.
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